Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Multiplex Assay Detects Atypical Bacterial Respiratory Pathogens

By LabMedica International staff writers
Posted on 12 May 2011
A single tube assay has been developed that can rapidly detect three atypical bacterial pathogens in clinical specimens from patients with suspected pneumonia. More...


The multiplex polymerase chain reaction (PCR) assay was compared with singleplex assays to determine the presence of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella species and the human ribonuclease P (RNase P) gene.

Scientists at the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA), used four distinct hydrolysis probes to detect three of the leading causes of community-acquired pneumonia. The assay was evaluated for specificity and sensitivity by testing against 35 related organisms, a dilution series of each specific target and 197 clinical specimens. In total, 177 nasopharyngeal and/or oropharyngeal swabs were tested by all four singleplex assays in addition to the multiplex assay. Twenty clinical specimens including lung tissue, bronchial lavage, sputa, and spleen tissue were also tested, in triplicate, with the singleplex assay designed specifically to detect Legionella species (Pan-Leg), as well as the multiplex assay.

A comparison to previously validated singleplex real-time PCR assays for each agent was also performed and specificity testing demonstrated no cross-reactivity. The analytical sensitivity for specific pathogen targets in both the singleplex and multiplex was identical at 50 fg, while efficiencies ranged from 82% to 97% for the singleplex assays and from 90% to 100% for the multiplex assay. This multiplex assay provides an overall improvement in the diagnostic capability for these agents by demonstrating a sensitive, high-throughput and rapid method. This procedure may allow for a practical and efficient means to test respiratory clinical specimens for atypical pneumonia agents in health care settings and facilitate an appropriate public health response to outbreaks.

The authors concluded that the use of this assay in surveillance studies may provide greater insight into the etiology and prevalence of atypical bacterial pneumonias among a population. The assay will also facilitate the rapid identification of the causative agent for community acquired pneumonia outbreaks. Widespread availability of this and similar assays may lead to a more effective public health response and expedite appropriate treatment of patients. The study was published in May 2011 in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
US Centers for Disease Control and Prevention


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.